Search hospitals > New Jersey > Newark
Rutgers New Jersey Medical School
Claim this profileNewark, New Jersey 07103
Global Leader in Cancer
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Squamous Cell Carcinoma
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
194 reported clinical trials
20 medical researchers
Summary
Rutgers New Jersey Medical School is a medical facility located in Newark, New Jersey. This center is recognized for care of Cancer, Human Immunodeficiency Virus Infection, Squamous Cell Carcinoma, Adenocarcinoma, Breast Cancer and other specialties. Rutgers New Jersey Medical School is involved with conducting 194 clinical trials across 325 conditions. There are 20 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Coral Omene, MD, PhD.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
Stage II
2Human Immunodeficiency Virus Infection
Global LeaderTop PIs
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Eugenia Girda, MDRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Cancer
Studies Ovarian Cancer
14 reported clinical trials
29 drugs studied
Coral Omene, MD, PhDRutgers Cancer Institute of New Jersey1 year of reported clinical research
Studies Breast Cancer
Studies Cardiotoxicity
7 reported clinical trials
23 drugs studied
Clinical Trials running at Rutgers New Jersey Medical School
Breast Cancer
Prostate Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Laryngeal Cancer
Cancer
Gallbladder Cancer
Lip and Oral Cavity Cancer
Anal Cancer
Laryngeal Squamous Cell Carcinoma
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Pre-Surgery Radiation Boost
for Breast Cancer
This phase II trial investigates the safety of delivering a part (boost) of radiation treatment before breast surgery in treating patients with breast cancer that has not spread to other places in the body (non-metastatic). Radiation therapy uses high energy photons/electrons to kill tumor cells and shrink tumors. Delivering a boost radiation treatment before surgery when doctors can still visualize the tumor on imaging may help to better target the tumor and decrease the volume of normal irradiated tissue. By so doing, doctors may achieve better cosmetic outcomes and possibly better tumor control.
Recruiting1 award N/A8 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Rutgers New Jersey Medical School?
Rutgers New Jersey Medical School is a medical facility located in Newark, New Jersey. This center is recognized for care of Cancer, Human Immunodeficiency Virus Infection, Squamous Cell Carcinoma, Adenocarcinoma, Breast Cancer and other specialties. Rutgers New Jersey Medical School is involved with conducting 194 clinical trials across 325 conditions. There are 20 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Coral Omene, MD, PhD.